Mylan NV (MYL)

40.25
0.53 1.30
NASDAQ : Health Technology
Prev Close 40.78
Open 40.90
Day Low/High 39.85 / 41.20
52 Wk Low/High 29.39 / 47.82
Volume 4.70M
Avg Volume 4.70M
Exchange NASDAQ
Shares Outstanding 514.78M
Market Cap 20.96B
EPS 1.30
P/E Ratio 31.32
Div & Yield N.A. (N.A)

Latest News

Mylan's Stock Gets Bump After Investor Day

Mylan's Stock Gets Bump After Investor Day

Following Wednesday's event, Leerink analyst Ami Fadia said she is 'incrementally more positive' on the drugmaker's pipeline and diversified business model and moved her rating to outperform.

Mylan Spotlights Diversification at Investor Day

Mylan Spotlights Diversification at Investor Day

The drug company generates about 60% of revenue outside the U.S.

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.

Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day

Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day

The pharmaceutical firm will conduct its investor day in New York City on April 11.

Mylan Introduces Symfi™ Triple Combo Once-Daily HIV Treatment In The U.S.

Mylan Introduces Symfi™ Triple Combo Once-Daily HIV Treatment In The U.S.

- Approval complements growing portfolio of cost-saving antiretroviral medications available to patients in the U.S., including recently announced Symfi Lo™ and Cimduo™

Mylan Adds To Growing Oncology Portfolio With Launch Of Generic Mutamycin® Injection

Mylan Adds To Growing Oncology Portfolio With Launch Of Generic Mutamycin® Injection

- Mitomycin for Injection is available to Mylan's hospital and other institutional customers -

Allergan CEO: We Are Looking at All Options to Create Shareholder Value

Allergan CEO: We Are Looking at All Options to Create Shareholder Value

Brent Saunders spoke at the Barclays healthcare conference, a few weeks after Mylan and Revance Therapeutics said they were teaming up on a proposed biosimilar of Allergan's Botox.

Generic Drug Sector Shifting With Legal Pressure, Changes at FDA

Generic Drug Sector Shifting With Legal Pressure, Changes at FDA

A massive price-fixing lawsuit brought by 45 states against a group of generic drug producers as well as a changing of the guard at the Food and Drug Administration may lead to changes in the generic drug sector.

Mylan Breaks Out Amid Generic Malaise; Target Shorts Rejoice -- ICYMI

Mylan Breaks Out Amid Generic Malaise; Target Shorts Rejoice -- ICYMI

Here's what you need to know now for Tuesday, March 6.

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.

Trimming Allergan

This is the exact type of strength we are looking for and recoups some of the cash we used earlier this morning.

Weekly Roundup

Volatility picked up this week due to news from Washington.

Mylan To Introduce Two New Cost-Saving HIV Combination Treatments In The U.S.

Mylan To Introduce Two New Cost-Saving HIV Combination Treatments In The U.S.

- FDA recently approved Symfi Lo™, a three-drug single-tablet antiretroviral (ARV) regimen, and Cimduo™, a double combination, for HIV treatment

Pressure May Be On Allergan to Strike a Major Deal, As Botox Gets Another Rival

Pressure May Be On Allergan to Strike a Major Deal, As Botox Gets Another Rival

Mylan and Revance Therapeutics say they have teamed up to develop and commercialize a proposed biosimilar or copy of Allergan's popular Botox, potentially ratcheting up pressure on the drugmaker.

Mylan Shares Jump After Earnings Beat

Mylan Shares Jump After Earnings Beat

The pharmaceutical company unveiled a collaboration and license pact with Revance Therapeutics to develop and commercialize a proposed biosimilar or copy of Allergan's Botox.

Updates on Nucor and Allergan

Nucor looks to gain on the expected tariffs announcement, while separately we're downgrading Allergan.

Mylan Becomes #25 Most Shorted Nasdaq 100 Component, Replacing Ross Stores

Mylan Becomes #25 Most Shorted Nasdaq 100 Component, Replacing Ross Stores

The most recent short interest data has been released for the 02/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Allergan Handed Patent Defeat Over Restasis

Allergan Handed Patent Defeat Over Restasis

Allergan's losing streak in a bid to stash patent rights protecting cash cow Restasis remains intact as the U.S. Patent Trial and Appeal Board rejects a move to dismiss a challenge brought by a trio of pharma companies.

Mylan Defeats Allergan's Maneuver To Rent Tribal Sovereign Immunity To Avoid Restasis® Patent Challenge

Mylan Defeats Allergan's Maneuver To Rent Tribal Sovereign Immunity To Avoid Restasis® Patent Challenge

U.S. Patent Trial and Appeal Board denies St. Regis Mohawk Tribe's motion to terminate Restasis patent challenge

16-Year Veteran Director Wendy Cameron To Retire From Mylan N.V. Board After 2018 AGM

16-Year Veteran Director Wendy Cameron To Retire From Mylan N.V. Board After 2018 AGM

Mylan Board Nominates Pauline van der Meer Mohr for Election to Board of Directors

UPS's Long-Tenured Board Members Are a Red Flag for Investors

UPS's Long-Tenured Board Members Are a Red Flag for Investors

The Atlanta-based company has five directors who have served beyond the average tenure of 8.2 years.

TheStreet Quant Rating: C+ (Hold)